The rest of this guide covers what each hormone does, how both move across a single cycle, what the ratio between them actually describes, how the pattern shifts through perimenopause, and why the day a sample is drawn can change a result more than anything happening inside your body.
Estrogen is the body's main growth and maintenance signal for reproductive tissue, and it also acts on bone, muscle, blood vessels, skin and the brain. The word describes a family rather than a single molecule. Estradiol is the most active form during the reproductive years and the one measured in a standard blood test as estradiol, usually abbreviated E2. Estrone becomes the more plentiful form after menopause, and estriol is mainly a hormone of pregnancy.
In cycling women, most estradiol comes from the granulosa cells of developing ovarian follicles, under direction from follicle stimulating hormone and luteinizing hormone released by the pituitary. Fat tissue, the adrenal glands and several other tissues also convert androgens into estrogens, which is why circulating estradiol never drops to zero, even once the ovaries stop releasing eggs. Men produce estradiol too, mostly by converting testosterone, and it matters for their skeleton and brain as well.
Inside the uterus, estradiol is the signal to proliferate, meaning it rebuilds the lining that was shed during a period. Outside the uterus, its receptors sit in tissues that have nothing to do with reproduction. Estradiol signalling reaches skeletal muscle, and research suggests that the drop in estradiol at menopause contributes to the loss of muscle mass and strength described as sarcopenia 1. Bone works on a similar principle, since estrogen restrains the cells that break bone down, and estrogen deficiency is associated with the accelerated bone loss seen in primary osteoporosis 2.
That breadth is the reason estradiol is worth measuring even when fertility is not the question. It is a structural hormone as much as a reproductive one.
Progesterone is the hormone the ovary produces after ovulation, and its job is to finish and steady what estrogen started. Once an egg is released, the collapsed follicle becomes the corpus luteum, a short-lived structure that makes progesterone for roughly two weeks. If pregnancy does not occur, the corpus luteum fades, progesterone falls and a period follows. Smaller amounts come from the adrenal glands in both sexes, and men carry low circulating levels as a precursor in steroid hormone production.
Because progesterone depends on ovulation having happened, it is the clearest blood clue that a cycle was ovulatory. Reference ranges, collection details and how a single value is read in context are covered in depth on the Progesterone marker guide. This page stays on how the two hormones work together.
The simplest way to hold the difference in mind is that estrogen builds and progesterone finishes. The table below sets out where each comes from, when it peaks and what it influences.
| Feature | Estrogen (measured as estradiol) | Progesterone |
|---|---|---|
| Main source in cycling women | Developing ovarian follicles | The corpus luteum, after ovulation |
| Other sources | Fat tissue, adrenal glands, conversion of androgens | Adrenal glands, placenta in pregnancy |
| When it peaks | Shortly before ovulation, with a smaller second rise in the luteal phase | Roughly a week after ovulation |
| Core job in the uterus | Builds and thickens the lining | Converts the lining into a stable, secretory state |
| Effects elsewhere | Bone, skeletal muscle, blood vessels, skin, brain | Body temperature, sleep, breathing drive, calming brain signalling |
| Basal body temperature | Little direct effect | Raises it after ovulation |
| Usual reporting units | pg/mL | ng/mL |
| Timing that makes a test readable | Early follicular for a baseline, or dated against symptoms | About seven days after ovulation |
Two practical points fall out of that table. First, the two hormones peak at different times, so a single blood draw captures one moment in a moving system rather than a fixed setting. Second, they are reported in different units, which matters whenever anyone quotes a ratio between them. A number that looks reassuring on one report can mean something quite different on another if the units, the cycle day or the assay are not the same.
They take turns, and that sequence is the entire logic of the menstrual cycle. Day one is the first day of bleeding, when both hormones sit low. Through the follicular phase, follicle stimulating hormone recruits a cohort of follicles, one becomes dominant, and the estradiol it produces climbs steadily. That rising estradiol rebuilds the uterine lining and, at its peak, flips pituitary feedback from negative to positive, triggering a surge of luteinizing hormone. Ovulation follows within a day or two.
The luteal phase then belongs to progesterone. The corpus luteum produces it in quantity, with levels peaking around the middle of the luteal phase, roughly seven days after ovulation. Estradiol also rises again during this stretch, though less steeply than before. If there is no pregnancy, the corpus luteum regresses, both hormones fall together, and the withdrawal of hormonal support is what brings on a period.
Those swings are not confined to the reproductive tract. Studies indicate that cyclical changes in estrogen and progesterone influence body temperature regulation, fuel use, the cardiovascular system and other aspects of physiology across the month 3. This is also why laboratory interpretation of estradiol and progesterone depends so heavily on knowing where in the cycle a sample was drawn 4.
In practice, this means a result is a snapshot with a timestamp. A progesterone value of a given size can be entirely expected on one cycle day and unexpected on another, with no change in the underlying biology.
The estrogen progesterone ratio describes which hormone's signal is relatively stronger at the moment of the blood draw. It is a way of framing a pattern, not a standalone test and not a diagnosis. There is no universally agreed cut-off for a healthy estradiol progesterone ratio, and most labs do not report one.
A few things make the ratio easy to misread. Estradiol is reported in pg/mL and progesterone in ng/mL, so a raw ratio depends entirely on whether someone converted the units first. Cycle day matters even more. A sample drawn in the mid-follicular phase, before ovulation has occurred, will almost always look estrogen-heavy, because progesterone has not risen yet. That is normal physiology rather than an imbalance. Compute a progesterone to estrogen ratio from a badly timed draw and you have measured the calendar, not the person.
Where the idea does earn its keep is as shorthand for a pattern seen repeatedly and in context. If luteal-phase draws across more than one cycle show progesterone that stays low while estradiol is well within its expected band, that pattern is worth discussing with a clinician, because it raises questions about whether ovulation is happening consistently. Interpretation still rests on the individual hormone values, the cycle day, the assay used and what the person is experiencing.
The popular term for a relatively high estrogen signal is estrogen dominance. It is useful everyday language, but it is not a formal laboratory category, and no single number confirms it.
In the uterus, estrogen and progesterone act in a strict order, and the second hormone's job is partly to limit the first. Estradiol drives the lining to proliferate. Progesterone then switches that tissue from growth into a differentiated, secretory state and holds it there. Without the progesterone phase, estrogen's growth signal is unopposed, which is why clinicians pay attention to prolonged stretches of estrogen exposure that are never followed by a progesterone rise.
That relationship can break down at the level of the receptor rather than the hormone. Research suggests that in endometriosis the endometrium responds poorly to progesterone while estrogen signalling remains strong, a pattern described as progesterone resistance 5. Progesterone resistance is associated with a range of gynaecological conditions in which tissue fails to respond normally even when circulating progesterone looks adequate on a blood test 6.
The practical takeaway is a limit on what bloodwork can tell you. A progesterone level measures how much hormone is in circulation. It does not measure how well target tissue is listening. Someone can have a luteal progesterone result inside the typical range and still have symptoms rooted in how the lining responds. This is one of the clearest cases where symptoms, imaging and a clinical history carry information that no biomarker can supply on its own.
Both hormones act on tissues far beyond the uterus, which is why their decline is felt as a whole-body change rather than a reproductive one. Estrogen's reach into the skeleton is the best characterised. It slows bone resorption, and estrogen deficiency is associated with the bone loss that defines primary osteoporosis 2. Skeletal muscle is similar in principle, and research suggests that falling estradiol contributes to the decline in muscle mass and strength that becomes more common after menopause 1.
The immune system also tracks the cycle. Research suggests that shifting estrogen and progesterone levels contribute to immune changes across the menstrual month, which may be relevant in people with autoimmune conditions whose symptoms follow a cyclical pattern 7.
The brain is the third major site. Estradiol and progesterone both act on neural systems involved in mood, sleep and stress response, and the hormonal instability of the menopause transition is associated with increased vulnerability to depressive symptoms during that window 8. Progesterone's calming reputation comes largely from one of its metabolites, which acts on the same receptor family that governs sedation, and it is part of why some people notice sleep and anxiety changes that track the luteal phase.
None of that makes a hormone result a verdict on mood, sleep or bone health. It does explain why a hormone pattern is worth reading alongside symptoms rather than in isolation.
Perimenopause changes the sequence before it changes the totals, and progesterone usually feels the change first. As the ovarian follicle pool shrinks, cycles become less predictable, and more of them pass without ovulation. A cycle with no ovulation produces no corpus luteum, which means little progesterone that month, even if bleeding still arrives on something resembling a schedule.
Estradiol behaves less tidily than most people expect. Rather than declining in a straight line, it often swings, with some cycles producing higher peaks than in earlier years and others producing very little. Meanwhile the pituitary pushes harder to recruit follicles, so fsh tends to rise and becomes more variable. Those changes are exactly why a single hormone panel taken during the transition is difficult to interpret on its own, and why laboratory assessment in this window is read as a pattern across markers and over time.
Symptoms often map onto that instability rather than onto low hormones as such. Hot flushes, disrupted sleep, heavier or closer-together bleeds, and mood changes can all show up while average hormone levels still look unremarkable. Hormonal fluctuation during the menopause transition is associated with a higher risk of depressive symptoms, through estradiol's effects on brain systems that regulate mood 8.
After menopause, defined by twelve consecutive months without a period, the picture settles. Progesterone stays low because ovulation has stopped, estradiol is low and relatively stable, and FSH stays elevated.
A low progesterone result most often reflects when the blood was drawn, not what the ovary can do. Progesterone is near the floor for the entire first half of a cycle, so a sample taken in the follicular phase is expected to be low. Before anything else is considered, the cycle day of the draw needs to be known.
When timing was correct, meaning the sample was taken in the mid-luteal window, a low reading may reflect a cycle in which ovulation did not occur, a luteal phase that was shorter than usual, or the irregular ovulation that becomes more common in perimenopause. Hormonal contraception is another common explanation, since methods that suppress ovulation change the hormonal pattern a blood test picks up 3. Significant physical stress, illness and large recent changes in training or energy intake can also disturb the signals that drive ovulation.
The sensible sequence is observation, then possible meaning, then a conversation. The observation is a number tied to a date. The possible meaning is that this particular cycle may not have been ovulatory, which a single test cannot confirm. The next step is usually to repeat the measurement in a properly timed window in a later cycle, alongside markers that describe the whole axis, and to review the result with a clinician who knows your history. A low value is suboptimal information rather than a diagnosis, and it should never be ignored or treated as settled.
An estradiol result only means something once the cycle day is attached to it, because the expected range at the start of a cycle, at the pre-ovulatory peak and after menopause barely overlap. A value described as low may simply be a correctly timed early follicular reading.
Genuinely low estradiol, found consistently and in the right context, may reflect reduced ovarian activity, which happens naturally after menopause and can also occur earlier when the signals from the pituitary are suppressed. A result that sits high may reflect a sample taken close to ovulation, more than one developing follicle, or the contribution of body composition, since fat tissue converts androgens into estrogens and adds to circulating levels. Laboratory method also matters more for estradiol than most markers, particularly at the low concentrations seen after menopause, where assay choice influences the number reported 4.
Symptoms sometimes attributed to high estrogen, including breast tenderness, bloating, heavier bleeding and mood swings, overlap heavily with symptoms of a low progesterone signal, with thyroid problems and with other conditions entirely. That overlap is precisely why the two hormones are read together, with the date of the draw, rather than one at a time. If a result sits outside your lab's stated range, bring it to a clinician who can decide whether it needs repeating, contextualising or further investigation.
Timing is the single biggest determinant of whether these two tests are interpretable. For a baseline estradiol, the conventional window is the early follicular phase, around days two to five of the cycle, usually drawn with FSH and luteinizing hormone so the whole axis can be read together. For progesterone, the window is the mid-luteal phase, about seven days after ovulation, which lands near day 21 in a textbook 28 day cycle and later in longer cycles. The widely used day 21 progesterone test is really a mid-luteal test wearing a convenient name, and it should be shifted when cycles run long or short.
| Measure | Typical lab reference range | FitScript optimal range |
|---|---|---|
| Progesterone, adult women (varies strongly by cycle phase) | 1 to 25 ng/mL | 5 to 20 ng/mL |
| Progesterone, adult men | 0.1 to 2 ng/mL | 0.2 to 1.4 ng/mL |
These are typical lab reference ranges, and they vary by laboratory, assay, age, sex and, for progesterone, cycle phase, so read your own result against the range printed on your report. FitScript's optimal ranges are optimization targets rather than diagnostic cut-offs, and a value outside them is a prompt for a conversation, not a conclusion. Estradiol is reported in pg/mL, and its expected ranges differ so widely between the follicular phase, the pre-ovulatory peak, the luteal phase and the post-menopausal years that a number carries little meaning without the collection date beside it 4.
With irregular cycles, a single draw is rarely enough, and testing across more than one cycle or anchoring the draw to tracked symptoms tends to be more informative. After menopause, cycle timing no longer applies.
Plenty of things move these results that have nothing to do with ovarian health, and most of them are worth ruling out before reading anything into a value. Cycle day is the largest, followed by the assay itself. Estradiol and progesterone can be measured by immunoassay or by mass spectrometry based methods, and the choice affects the number reported, particularly at low concentrations 4. That is also why comparing a result from one laboratory with one from another, months apart, often creates confusion that does not exist in the biology.
Hormonal contraception changes the picture substantially, because methods that suppress ovulation alter the cyclical hormone pattern a blood test is designed to capture 3. Pregnancy raises progesterone markedly. Acute illness, poor sleep, heavy training loads and periods of low energy availability can all disturb the pituitary signals that drive the cycle, which shows up downstream in both hormones. Body composition contributes too, since fat tissue converts androgens into estrogens.
There is also plain biological variability. Hormones are released in pulses, cycles vary from month to month in the same person, and two draws a day apart in the luteal phase can differ noticeably. The practical response is to standardise what you can, which means same laboratory, same approximate time of day, correct cycle day recorded on the requisition, and a repeat before drawing conclusions from one surprising number.
Estradiol and progesterone are easier to interpret when the rest of the axis is on the same report. Follicle stimulating hormone and luteinizing hormone describe the pituitary signals driving the ovary, and together with estradiol and progesterone they form the core group used in laboratory assessment of women's hormonal health 4. A high FSH with a low estradiol tells a different story from a low FSH with a low estradiol, even though the estradiol value is identical.
Sex hormone binding globulin is worth including because it determines how much of the circulating hormone pool is free and active. Total and free testosterone and DHEA sulphate fill in the androgen side, which is relevant to cycle irregularity, skin and hair changes. Prolactin is checked when cycles have become infrequent or have stopped, since it can suppress ovulation. Thyroid markers, usually TSH with free T4, belong in the same panel, because thyroid dysfunction produces fatigue, cycle changes and mood symptoms that mimic a hormone pattern problem.
Metabolic markers are the last piece. Fasting insulin, HbA1c and a lipid panel describe the background on which sex hormones act, and insulin resistance is a common driver of irregular cycles. Reading these together turns a single ambiguous number into a pattern, which is where useful questions come from.
Any result outside your laboratory's stated range deserves a conversation, and some symptoms warrant one regardless of what the bloodwork says. Bleeding after menopause, bleeding that is unusually heavy or prolonged, bleeding between periods, severe pelvic pain, cycles that stop for several months without pregnancy, or symptoms that are limiting daily life are all worth discussing with a clinician promptly, because they are evaluated clinically rather than by hormone panel alone.
For everything else, the useful frame is pattern over time rather than reaction to a single value. Bring the collection date and cycle day with you, bring prior results if you have them, and bring a record of symptoms, since the combination answers questions that blood values cannot. A clinician can decide whether a result needs repeating in a better-timed window, whether imaging or additional markers are appropriate, and whether anything beyond monitoring is warranted. Any therapy that might follow is a decision for a licensed provider who has evaluated whether it is appropriate for you, and no article can make that call.
This page is educational and is not medical advice. Discuss your results, and any treatment that might follow, with a clinician or licensed provider who knows your history.
If you want these markers measured together rather than one at a time, the hormone complete her panel groups the main female hormone markers into a single draw. FitScript's membership includes 150+ biomarkers tested per year, with Atlas, its AI health advisor, interpreting the pattern and a licensed provider deciding on any clinical next step.
Estrogen is the building hormone, thickening the uterine lining in the first half of the cycle and acting on bone, muscle, skin and brain. Progesterone is the stabilizing hormone, released after ovulation, that converts the lining into a settled, secretory state. They act in sequence, so each one depends on the other doing its part first.
The useful window is the mid-luteal phase, roughly seven days after ovulation, which falls near day 21 in a 28 day cycle. In longer or shorter cycles the draw should be moved so it still lands about a week after ovulation. A sample taken in the first half of the cycle will be low by design and tells you very little.
Typical lab reference ranges for adult women run from about 1 to 25 ng/mL, and from about 0.1 to 2 ng/mL in men, with the female figure depending heavily on cycle phase. FitScript's optimal ranges are 5 to 20 ng/mL for women and 0.2 to 1.4 ng/mL for men, and those are optimization targets rather than diagnostic cut-offs. Always read your own result against the range printed on your report.
Yes, they are usually drawn together, which is one reason cycle timing matters so much. A mid-luteal draw captures both a meaningful progesterone value and the secondary estradiol rise. An early follicular draw gives a clean estradiol baseline alongside FSH, but progesterone will be low at that point for ordinary reasons.
Not on its own. The most common explanation is simply that the sample was drawn on the wrong cycle day, and the second most common is a single cycle in which ovulation did not occur. A correctly timed low value across more than one cycle is worth reviewing with a clinician, who can decide whether to repeat it or look further.
It describes which hormone's signal is relatively stronger at the moment the blood was taken, nothing more. Because the two are reported in different units and both change by the day, the ratio shifts dramatically depending on when you draw. Clinicians generally read the individual values with the cycle day attached rather than relying on a ratio.
Estradiol is often worth measuring in men, since it is made by converting testosterone and matters for bone and brain health. Progesterone sits at low levels in men and is usually checked only when there is a specific reason, since it functions mainly as a precursor in steroid hormone production. A clinician decides which markers belong on a given panel.
Progesterone usually drops away first, because cycles without ovulation become more frequent and no corpus luteum means little progesterone that month. Estradiol tends to swing rather than fall steadily, and FSH rises and becomes more variable. For that reason a single panel during the transition is hard to interpret, and testing across time is more informative.